To our knowledge, this study is the first to evaluate the cost-effectiveness of oral semaglutide 14 mg once daily in Chinese patients with T2DM who are poorly controlled on basal insulin using a diabetes-specific model. Here, INS is linked to type 2 diabetes mellitus.